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Purpose or Objective: To independently validate patient-
specific quality assurance (QA) methods, clinically used in the 
Netherlands, for IMRT and VMAT plans using the same set of 
treatment plans for all institutes. 
 
Material and Methods: A set of treatment plans was devised: 
simple and more complex IMRT/VMAT and a stereotactic 
VMAT plan, all 6MV for both Varian and Elekta linacs. Ten 
plans were used for Varian linacs (5 for True Beam and 5 for 
Clinac) and 9 for Elekta linac(4 for MLCi and 5 for Agility). 
The plans were imported in the participating institute’s 
treatment planning system for dose computation on the CT 
scan of the audit phantom (provided by the audit team 
together with the plans). Additionally, 10x10 cm2 fields were 
made and computed on both phantoms. Next, the audit team 
performed measurements using the audit equipment. All 21 
Dutch radiotherapy institutes were audited. The 
measurements were performed using an ionization chamber 
(PinPoint, PTW), Gafchromic EBT3 film and a 2D ionization 
chamber array, all in an octagonal phantom (Octavius, PTW). 
Differences between the measured and computed dose 
distribution were investigated using a global gamma analysis 
with a 5%/1mm criterion for the stereotactic VMAT plan and 
3%/3mm for the other plans with a 95% pass rate tolerance. 
Additionally, the participating centres performed QA 
measurements of the same treatment plans according to 
their local protocol and equipment. 
 
Results: The average difference between the point 
measurement, at the centre of the phantom, and the planned 
dose is below 1% (range: (-4.0 – +2.0)%) independently on the 
plan type (table 1).  
 
 
 
As shown in figure 1 the average pass rate obtained from the 
array measurements is in good agreement (average 
difference: (0.4 ± 1.0)%) with the average pass rate of the QA 
measurements provided by the participating institutes 
performed with their equipment for all the plans except for 
the simple VMAT plan.  
 
 
 
For the latter, the pass rate obtained with the Octavius is 
influenced by the sensitivity variation of the array as a 
function of gantry angle. Seven institutes out of 21 had plans 
that failed the audit gamma analysis pass rate tolerance of 
95% while the institute’s QA outcome was within tolerance (1 
institute two plans, 6 institutes one plan). The film 
measurement results are still under investigation and 
therefore not presented in this abstract. 
 
Conclusion: The results demonstrate that such a national QA 
audit is feasible. The reported in-house QA results were 
consistent with the audit despite differences in dosimetry 
equipment and analysis methods. Of the 21 Dutch centres 
audited, 67% passed the gamma analysis test for all the plans 
measured with a 2D-array by the audit team showing 
acceptable implementation of IMRT and VMAT delivery.  
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Purpose or Objective: Radiotherapy with grids has previously 
been carried out with photon beams. The grid method is used 
as an attempt to exploit the clinical finding that normal 
tissue can tolerate higher doses as the irradiated volumes 
become smaller. In this work we investigated the possibilities 
to perform proton-beam grid therapy (PBGT) with millimeter-
wide proton beams by performing Monte Carlo simulations of 
dose distributions produced by such grids. We also prepared 
proton-grid treatment plans with a TPS, using real patient 
data and beam settings available at modern proton therapy 
centers. 
 
Material and Methods: Monte Carlo calculations were 
performed using TOPAS version 1.2.p2 in a 20x20x20 cm3 
water tank. The beam grids (each containing 4x4 proton 
beams arranged in a square matrix) were aimed towards a 
cubic target at the tank center. A total of 2x2 opposing grid 
angles were used. The target was cross-fired in an interlaced 
manner. A beam-size study was carried out to find a suitable 
elemental beam size regarding beam thinness, peak-to-
entrance dose ratio and lateral penumbra along the beam 
path. Dose distributions inside and outside of the target were 
calculated for beam center-to-center (c-t-c) separations 
inside the grids of 6, 8 and 10 mm. 
The TPS study was performed with Varian Eclipse. We re-
planned two patients (one liver cancer and one rectal cancer 
patient) already treated in the hospital with photon therapy 
with the suggested PBGT. The IMPT method was used to 
prepare these plans. The plan objectives were set to create a 
homogeneous dose inside the target. 
 
Results: A beam size of 3 mm (FWHM) at the tank surface 
was found suitable from a dosimetric point of view for the 
further studies. By interlacing simulated beam grids from 
several directions, a cubic and nearly homogeneous dose 
distribution could be achieved in the target (see Figure 1). 
The c-t-c distance was found to have a significant impact on 
the valley dose outside of the target and on the homogeneity 
of the target dose. In the TPS study, a rather uniform dose 
distribution could be obtained inside of the contoured PTV 
while preserving the grid pattern of the dose distribution 
outside of it. The latter finding could be important for tissue 
repair and recovery. 
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Conclusion: Proton-beam grids with 3 mm beam elements 
produce dose distributions in water for which the grid pattern 
is preserved down to large depths. PBGT could be carried out 
at proton therapy centers, equipped with spot-scanning 
possibilities, using existing tools. However, smaller beams 
than those currently available could be advantageous for 
biological reasons. With PBGT, it is also possible to create a 
more uniform target dose than what has been possible to 
produce with photon-beam grids. We anticipate that PBGT 
could be a useful technique to reduce both short- and long-
term side effects after radiotherapy. 
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Purpose or Objective: Currently, various MR-guided 
radiotherapy systems are being developed and clinically 
implemented. For conventional radiotherapy, Electronic 
Portal Imaging Devices (EPIDs) are frequently used for in vivo 
dose verification. The high complexity of online treatment 
adaptation makes independent dosimetric verification in the 
Elekta MR-linac combination indispensable. One of the 
challenges for MR-linac portal dosimetry is the presence of 
the MRI housing between the patient and the EPID. 
The purpose of this study was to adapt our previously 
developed back-projection algorithm for the presence of the 
MRI scanner. 
 
Material and Methods: Three steps have been added to our 
current EPID dosimetry back-projection model to account for 
the presence of the MRI scanner: i) subtraction of scatter 
from the MRI to the EPID, ii) correction for the MRI 
attenuation, iii) compensation for changes in the beam 
spectrum. The calibration of the algorithm needs a set of 
commissioning data (from EPID and ionization chamber, both 
with and without the MRI) to determine the parameters for 
the back-projection method. 
An aluminum block of 12 cm thickness at 15 cm distance from 
the EPID was used to approximate the effects of the MRI 
scanner. Measurements were performed using a 6MV photon 
beam of a conventional SL20i linear accelerator (Elekta AB, 
Stockholm, Sweden) at 0° gantry. 
58 IMRT fields of 11 plans (H&N, lung, prostate and rectum) 
were delivered to a 20 cm polystyrene slab phantom and 
portal images were acquired with the aluminum plate in 
place. For independent comparison with our conventional 
method the same fields were delivered without the aluminum 
plate. The EPID images were converted to dose, corrected for 
the presence of the aluminum plate, back-projected into the 
phantom and compared to the planned dose distribution 
using a 2-D gamma evaluation (3%, 3 mm). 
 
Results: The γ_mean averaged over the 58 IMRT fields was 
0.39±0.11, the γ_1% was 1.05±0.30 and the %_γ≤1 was 
95.7±5.3. The dose difference at the isocenter was -0.7±2.2 
cGy. These results are in close agreement with the 
performance of our algorithm for the conventional linac 
setup (Table 1). 
 
 
 
Conclusion: Our EPID dosimetry back projection algorithm 
was successfully adapted for the presence of an attenuating 
medium between phantom (or patient) and EPID. 
Experiments using a 12 cm aluminum plate (approximating 
the MR-linac geometry) showed excellent agreement 
between planned and EPID reconstructed dose distributions. 
This result is an essential step towards an accurate, 
independent, and potentially fast field-by-field IMRT portal 
dosimetry based verification tool for the MR-linac. 
Part of this research was sponsored by Elekta AB.  
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Purpose or Objective: Hyperthermia is a (neo)adjuvant 
treatment modality that increases the effectiveness of 
radiotherapy or chemotherapy by heating the tumour area to 
41–43 °C. Loco-regional hyperthermia is delivered using 
phased array systems with individually controlled antennae. 
Hyperthermia treatment planning is necessary to determine 
the phase and amplitude settings for the individual antennae 
that result in the optimal temperature distribution. Current 
treatment planning systems are accurate for solid tissues but 
ignore the specific properties of the urinary bladder and its 
contents, which limits their accuracy in the pelvic region. 
This may have clinical implications for such treatment sites 
as the rectum, the cervix uteri, and the bladder itself.  
